Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (460)	3/8/1999 5:39:00 PM
From: LLCF	Respond to of 613

<and the trend in GLGC sure does not look good..> At the risk of "chatting" I'll say that my "RSI" chart shows that this thing is WAY OVERSOLD... I'm in tomorrow if the stock opens here or lower just for a trade. I'd love comments about the overall outlook in the database stocks as it relates to the size and complexity of the market... ie. it sounds to me that there is so much potentially useful information out there to be mapped, and disected and remapped, updated etc. that this whole patent issue maybe just a "bonus" to these companies... is there a limit to the value that can be added to these databases even if the "genome map" itself is public domain? Just "chattering", would like to keep the comentary going on the subject. DAK

To: Mike McFarland who wrote (460)	3/8/1999 6:07:00 PM
From: WWS	Read Replies (1) \| Respond to of 613

One that I've followed, but never purchased, just flamed out on its IND application with a 7-4 vote against approval by its FDA advisory committee. Product was a topical antibiotic salve being tested for diabetic foot ulcers. Salve was derived from magainins, a peptide classification first found in frog skin. Company is Magainin (MAGN) and now trades about 1 1/2. They still have squalamine (from sharks) in the wings pre clinical for possible anti-cancer tx. But company may not be able to raise sufficient funds on their own to take another product through p-III.